Track sentiment, discussions and live quotes, post ideas and see what real traders are doing

CoreWeaves quarterly results beat expectations and management raised its outlook, but the stocks muted, volatile reaction reflects a debate over whether strong AI demand can justify heavy capital spending, debt and rising interest costs. Bulls point to growth and contracted demand, while bears worry about cash burn and possible dilution.

Netlists third-quarter results and earnings call are driving attention, with traders focused on sharply improved profitability and margins, cash from the Samsung license, and expected recurring licensing revenue. Many see the results as a step toward more sustainable growth, while others question the steep quarter-over-quarter drop in product sales and await clearer guidance and updates on SK hynix.

Attention centers on the pending FDA decision on Capricors DMD treatment deramiocel, with traders parsing CEO Lindas comments that she is bullish on the cardiac data while declining to disclose label details. The community remains largely hopeful about approval and launch readiness, but debate over whether cardiac benefits will be included in the initial labeland the lack of a clear regulatory updatehas tempered that optimism.

NVIDIAs selloff is dominated by concerns over CEO Jensen Huangs admitted affair and allegations that the woman involved had ties to Chinese intelligence, prompting a board investigation and debate about disclosure, export-control risks, and his future as CEO. Traders are split between calling the drop an overreaction and buying the dip on confidence in AI-chip demand, and anticipating further losses if the investigation leads to Huangs departure.

Rigetti is drawing attention after its quarterly results missed revenue expectations and its full-year outlook fell short, renewing concerns about its high valuation, cash burn, and lack of commercial scale. Bears view the results as evidence that the business is lagging, while bulls argue that progress in quantum-chip performance and government backing support the long-term technology case.

Amprius Q3 results and higher full-year outlook are driving attention, but an EPS miss and continued losses have weighed on the shares despite stronger revenue growth. Traders are split between viewing the selloff as an overreaction to otherwise encouraging results and focusing on profitability and dilution risks.

Fireflys third-quarter results are the main focus, with traders highlighting a revenue and adjusted-EPS beat, strong backlog, and the outlook while debating why the shares did not rise. Optimists point to the large AST SpaceMobile engine deal and future contract potential; skeptics remain concerned about cash burn and execution.

Nebiuss upcoming quarterly results are the focus, with traders treating CoreWeaves strong report and raised outlook as a read-through for AI-compute demand and a possible positive signal for NBIS. Optimism about a revenue beat is tempered by debate over Nebiuss capacity expansion, funding needs and financing risks, amid recent weakness in neocloud shares.

LightPaths fiscal Q1 results are driving discussion, with traders highlighting revenue growth, a larger backlog, and strong order activity while waiting for managements outlook on the earnings call. Reactions are mixed: some see evidence the growth story is progressing, while others question whether the results are enough to reverse weak price action and justify the companys potential.

Kuras quarterly update has put KOMZIFTIs commercial ramp in focus, with traders highlighting growth in prescriptions and new patient starts. Debate also centers on Johnson & Johnsons menin-inhibitor data as a potential competitive threat: some see it pressuring Kuras frontline AML prospects, while bulls argue the comparisons are incomplete and emphasize Kuras launch progress.